CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net income	$ (69,654)	$ 64,707	$ 7,872
Less: Income (loss) from discontinued operations, net of income taxes	(16,048)	73,047	8,296
Loss from continuing operations, net of income taxes	(53,606)	(8,340)	(424)
Adjustments to reconcile net loss from continuing operations to net cash provided by (used in) operating activities:
Depreciation	13,555	8,513	6,591
Amortization of intangibles	6,671	3,957	3,376
Amortization of deferred financing costs	2,259	1,261	1,055
Change in fair value of contingent consideration	(5,786)	0	0
Change in deferred income tax	4,816	(4)	1,153
Compensation under stock-based compensation plans	9,450	6,122	4,467
Loss on disposal of fixed assets	0	156	201
Loss on extinguishment of debt	15,898	0	0
Equity in earnings of unconsolidated affiliate	675	0	0
Changes in assets and liabilities, net of acquired businesses:
Receivables, net of bad debt expense	(31,861)	101,230	(31,690)
Inventory	4,939	(15,249)	(2,497)
Prepaid expenses and other assets	(420)	3,726	11,211
Accounts payable	22,136	(48,200)	(1,659)
Claims payable	(4,864)	(4,354)	8,729
Amounts due to plan sponsors	(13,084)	(7,046)	5,437
Accrued interest	(3,627)	(22)	59
Accrued expenses and other liabilities	(5,656)	8,112	(2,945)
Net cash provided by (used in) operating activities from continuing operations	(38,505)	49,862	3,064
Net cash provided by (used in) operating activities from discontinued operations	(16,048)	(22,978)	23,905
Net cash provided by (used in) operating activities	(54,553)	26,884	26,969
Cash flows from investing activities:
Purchases of property and equipment, net	(25,626)	(10,986)	(7,853)
Cash consideration paid for acquisitions, net of cash acquired	(282,998)	(43,046)	(463)
Cash consideration paid for unconsolidated affiliate, net of cash acquired	(8,617)	0	0
Cash advances to unconsolidated affiliate	(2,363)	0	0
Cash consideration paid to DS Pharmacy	0	(2,935)	0
Cash consideration paid for unconsolidated affiliate, net of cash acquired	0	10,652	0
Net cash used in investing activities from continuing operations	(302,370)	(67,619)	(8,316)
Net cash provided by (used in) investing activities from discontinued operations	0	161,499	(1,591)
Net cash provided by (used in) investing activities	(302,370)	93,880	(9,907)
Cash flows from financing activities:
Proceeds from stock offering	118,382	0	0
Proceeds from new credit facility, net of fees paid to issuers	378,091	0	0
Repayment of 10 1/4% senior unsecured notes	(237,397)	0	0
Deferred and other financing costs			(22)
Borrowings on line of credit	449,559	1,244,050	1,773,644
Repayments on line of credit	(409,559)	(1,307,872)	(1,791,058)
Principal payments of long-term debt	(5,000)	0	0
Repayments of capital leases	(802)	(3,278)	(2,635)
Net proceeds from exercise of employee stock compensation plans	2,549	8,611	3,198
Surrender of stock to satisfy minimum tax withholding	0	(174)	(189)
Net cash provided by (used in) financing activities	295,823	(58,663)	(17,062)
Net change in cash and cash equivalents	(61,100)	62,101	0
Cash and cash equivalents - beginning of period	62,101	0	0
Cash and cash equivalents - end of period	1,001	62,101	0
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	22,598	25,589	27,528
Cash paid during the period for income taxes, net of refunds	242	3,137	1,042
DISCLOSURE OF NON-CASH TRANSACTIONS:
Capital lease obligations incurred to acquire property and equipment	$ 145	$ 20	$ 6,631